ClinicalTrials.gg
CompletedNCT04088357Updated Jun 24, 2021

Efficacy of Topical TolaSure on Acute Induced Wounds in Healthy Participants

A Phase 2 interventional study of TolaSure Topical Gel and Topical Vehicle Gel in Wound Healing, sponsored by BioMendics, LLC. Completed at 2 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-06-24.

Sponsored by BioMendics, LLC · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Apr 2020, 6 years 6 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Jun 2021.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

TolaSure is a topical gel for the promotion of accelerated wound healing. This phase II study will primarily assess the efficacy of TolaSure when applied to skin wounds created by punch biopsy in healthy participants. Safety, cutaneous tolerability, wound pain control, and quality of healing will also be assessed. A total of 80 healthy volunteers, males and females ages 18 years or older, will be enrolled. Subjects will be monitored for safety and efficacy until wound closure (estimation about 8 weeks) following topical administration of TolaSure.

02

Conditions studied

  • Wound Healing

Keywords

  • Healthy Participants
  • Skin
  • Dermal
  • Biopsy
03

In context

Lead sponsor

BioMendics, LLC is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy Males and Females > 18 years of age
  • Health history review
  • Physical exam
  • Blood and urine clinical chemistries
  • Negative pregnancy test

Exclusion criteria

Exclusion Criteria:

  • Acute or chronic skin disorders (e.g. psoriasis);
  • Acne or dermatitis at the test site;
  • Prone to keloids or hypertrophic scarring;
  • Topical or systemic antibiotics within 4 weeks of study enrollment;
  • Subjects with known severe mental illness which, in the investigator's opinion, may prevent or interfere with the subject's ability to comply with study protocol procedures;
  • Diagnosed with Diabetes Type I/II or glucose results indicative of prediabetic condition;
  • Morbidly obese with a (BMI) ≥ 40;
  • Surgery within the previous 3 months (except for minor cosmetic or dental procedures)
  • History of severe vitamin or mineral deficiency;
  • History of drug or alcohol abuse (as defined by the Investigator);
  • Smoking/Vaping;
  • /AIDS;
  • Consistently taking and/or non-steroidal anti-inflammatory drugs. Subjects may use NSAIDs on an as needed basis with no more than 7 days of consecutive use;
  • Cancer diagnosis in the last 5 years;
  • Currently receiving chemotherapy or radiation;
  • Women who are pregnant, nursing, or planning a pregnancy;
  • Hyper- or hypo-pigmentation, or tattoos in the area where they will place the test fields;
  • Symptoms of a illness in the four weeks before treatment application that may influence the outcome of the study;
  • Treatment with any agent within one month before treatment application for this trial;
  • Unwilling or unable to comply with the requirements of this protocol, including the presence of any condition (physical, mental, or social) that is likely to affect the subject's return for follow-up visits on schedule;
  • Other unspecified reasons that, in the opinion of the Investigator, make the subject unsuitable for enrollment.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
72 participants (actual)

Study arms

  • Active comparator
    5 Percent TolaSure Topical Gel

    5%(w/w) TolaSure Gel

    Drug: TolaSure Topical Gel

  • Placebo comparator
    Topical Vehicle Gel

    Vehicle Gel

    Drug: Topical Vehicle Gel

Interventions

  • DrugTolaSure Topical Gel

    TolaSure topical gel is applied to skin punch biopsies daily for the first seven consecutive days, then three times a week, defined as every two to three days, until closure.

    Also known as: Active Ingredient BM-3103

  • DrugTopical Vehicle Gel

    TolaSure Vehicle Gel is applied topically to skin punch biopsies daily for the first seven consecutive days, then three times a week, defined as every two to three days, until closure.

    Also known as: TolaSure Vehicle Gel

06

What researchers measure

Primary outcomes

  1. Accelerated Wound Closure

    Time-to-closure will be calculated by the number of days from biopsy to wound closure. Wound closure (changes in wound area (mm\^2) over time) will be determined by the digital imaging platform software with Principal Investigator confirmation.

    Time frame: Day 1, 2, and 7, then weekly until closure (estimated 8 weeks)

Secondary outcomes

  1. Percent Area Reduction after Four Weeks

    Wound area measurements (mm\^2) will be calculated at week 4 by using a digital imaging. A percent reduction in area at week 4 will be calculated by comparing the initial area of the biopsy at Day 1 to the week 4 biopsy area.

    Time frame: Week 4

  2. Wound Pain Control

    Wound-related pain or discomfort will be assessed, using the Visual Analog Scale (VAS) for Pain, for each individual wound site as pain at rest followed by pain to touch. The VAS Pain is a continuous scale comprised of a horizontal line, 10 centimeters (100 mm) in length. Pain will be defined per the following scale: None - 0-4 mm; Mild - 5-44 mm: Moderate - 45-74; Severe - 75-100 mm

    Time frame: Day 2 and 7, then weekly until wound closure (estimated 8 weeks)

  3. Quality of Healing

    Patient and Observer Scar Assessment Scale (POSAS) version 2.0 will be used to assess the quality of healing of each biopsy site at the end of the study once both wounds are closed.

    Time frame: End of study (estimated 8 weeks)

  4. Cutaneous Tolerability

    Cutaneous tolerability will include an evaluation of erythema and edema following the modified Draize scoring system. Draize scores will be recorded and changes from baseline Draize scores will be monitored over the course of the time frame. Draize Scoring System. Erythema: 0-No Erythema, 1-Slight Erythema, 2-Well Defined Erythema, 3- Moderate or Severe Erythema, 4- Severe Erythema or slight eschar formation. Edema: 0- No Edema, 1- Very Slight Edema(barely perceptible), 2-Slight Edema (well defined edges), 3-Moderate Edema (raised \>1mm), 4- Severe Edema (raised \>1mm and extending beyond the area of exposure)

    Time frame: Day 1, 2, and 7, then weekly until wound closure (estimated 8 weeks)

  5. Blood and Urine Chemistries

    Absolute values and changes over time of clinical chemistries including; Absolute values and changes over time of clinical blood and urine chemistries including; Hematology and Coagulation, Coagulation, Serum Chemistry, and Urinalysis. Blood and urine analytes are measured on a per mL basis.

    Time frame: Screening, Day 2 and 7, then weekly until wound closure (estimated 8 weeks)

07

Study locations

2 sites
  • University of Miami
    Miami, Florida 33136, United States
  • J&S Studies
    College Station, Texas 77845, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2019 to primary completion in Apr 2020, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2019
First posted
Sep 12, 2019
StartActual
Aug 26, 2019
Primary completionActual
Apr 22, 2020
CompletionActual
Apr 22, 2020
Results delay requested
Jun 2, 2021
Last update
Jun 24, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04088357
Lead sponsor
BioMendics, LLC
Collaborators
Symbio, LLC
Responsible party
Sponsor
First posted
Sep 12, 2019
Start date
Aug 26, 2019
Primary completion
Apr 22, 2020
Completion
Apr 22, 2020
Last update
Jun 24, 2021

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion